Bio-Rad Laboratories (BIO) vs Cytek Biosciences (CTKB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cytek Biosciences (CTKB) has outperformed Bio-Rad Laboratories (BIO) over the past year, gaining 40.9% versus a gain of 24.1%. Over five years, BIO leads with a -49.0% price change compared with -77.8% for CTKB. Bio-Rad Laboratories is the larger company by market cap ($9.52 billion vs $677.2 million), about 14.1 times the size.
On valuation, Bio-Rad Laboratories trades at a lower forward P/E (35.9x vs 74.4x for Cytek Biosciences).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIO | CTKB |
|---|---|---|
| Share price | $355.93 | $5.21 |
| Market cap | $9.52B | $677.20M |
| 1-day change | -3.26% | -2.44% |
| YTD return | +21.43% | +5.74% |
| 1-year return | +24.08% | +40.90% |
| 5-year return | -49.00% | -77.81% |
| P/E ratio (TTM) | 45.11 | — |
| Forward P/E | 35.89 | 74.43 |
| EPS (TTM) | $7.89 | $-0.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.58B | — |
| Revenue growth (YoY) | +0.65% | — |
| Net income (latest FY) | $759.90M | — |
| Gross margin | 51.87% | — |
| Operating margin | 1.83% | — |
| Net margin | 29.42% | — |
| 52-week high | $396.23 | $6.21 |
| 52-week low | $236.73 | $3.31 |
| Distance from 52-week high | -10.17% | -16.10% |
| Analyst consensus | hold | none |
| Avg. price target upside | -7.75% | +6.72% |
| Average volume | 276.93K | 1.04M |
| Shares outstanding | 21.68M | 129.98M |
| Employees | 7,450 | 682 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Bio-Rad Laboratories is about 14.1 times larger than Cytek Biosciences by market value ($9.52B vs $677.20M).
- CTKB has outperformed BIO by 16.8 percentage points over the past year.
About Bio-Rad Laboratories
BIO stock →Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.
Industrials · Biotechnology: Laboratory Analytical Instruments · 7,450 employees
About Cytek Biosciences
CTKB stock →Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems.
Industrials · Biotechnology: Laboratory Analytical Instruments · 682 employees
BIO vs CTKB FAQ
Which is bigger, Bio-Rad Laboratories or Cytek Biosciences?
Bio-Rad Laboratories (BIO) is larger, with a market capitalization of $9.52B compared with $677.20M for Cytek Biosciences (CTKB).
Which stock has performed better over the past year, BIO or CTKB?
CTKB returned +40.90% over the past 12 months, compared with +24.08% for BIO (price return, excluding dividends). Past performance does not predict future results.
Are Bio-Rad Laboratories and Cytek Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.